Clinical Trials

LymphoidOther hematologic neoplasm

49 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01841736 2026-05-27

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

171 enrolled 15 charts

EndocrineNET

Neuroendocrine Tumors

NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

CNSEndocrineGastrointestinalGenitourinarySarcoma

109 enrolled 24 charts

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

CNSOther hematologic neoplasm

10 enrolled 11 charts

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03581292 2026-05-27

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

38 enrolled 13 charts

CNS

Astrocytoma, Glioblastoma, Glioma

NCT03595124 2026-05-27

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

15 enrolled 15 charts

Genitourinary

Carcinoma, Renal Cell

NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

20 enrolled 9 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04284774 2026-05-27

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidMyeloidSarcoma

5 enrolled 9 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Wilms Tumor, Neuroblastoma, Pheochromocytoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Thyroid Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04320888 2026-05-27

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

1 enrolled 3 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04439149 2026-05-27

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

24 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439188 2026-05-27

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

35 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT00070499 2026-05-26

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

MyeloidOther hematologic neoplasm

406 enrolled 11 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

29 enrolled 10 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT01708954 2026-05-26

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

125 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02890355 2026-05-20

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 2 Completed

123 enrolled 15 charts

Pancreatic Neoplasms

NCT02965716 2026-05-20

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

43 enrolled 18 charts

Dermatologic

Melanoma

NCT04175912 2026-05-20

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

40 enrolled 11 charts

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT01585805 2026-05-19

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

83 enrolled 23 charts

Pancreatic Neoplasms

NCT03367741 2026-05-19

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

82 enrolled 11 charts

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04439292 2026-05-19

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

44 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03047213 2026-05-13

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

17 enrolled 11 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03304639 2026-05-13

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Phase 2 Completed

9 enrolled 11 charts

Dermatologic

Carcinoma, Merkel Cell

NCT02314169 2026-05-12

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

143 enrolled 16 charts

Anal Canal Carcinoma, Anus Neoplasms

NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

54 enrolled 12 charts

Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT03210714 2026-05-12

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloid

20 enrolled 10 charts

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT06400251 2026-05-11

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Lymphoma, Multiple Myeloma

NCT04439110 2026-05-08

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

38 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439266 2026-05-07

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

5 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439279 2026-05-07

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439331 2026-05-07

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439344 2026-05-07

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

53 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439123 2026-05-06

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439175 2026-05-06

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

70 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06357988 2026-05-06

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

34 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT03155620 2026-05-05

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

1,377 enrolled 10 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT04034251 2026-05-05

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Phase 2 Terminated

12 enrolled 18 charts

GastrointestinalGynecologic

Adenocarcinoma, Peritoneal Neoplasms, Stomach Neoplasms

NCT05490771 2026-05-05

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Lymphoma, Multiple Myeloma

NCT06400238 2026-05-05

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Lymphoma, Multiple Myeloma

NCT02968810 2026-05-04

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

52 enrolled 15 charts

Fibrosis, Carcinoma, Hepatocellular

NCT03036930 2026-05-04

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

51 enrolled 10 charts

Papillomavirus Infections

NCT03660826 2026-05-04

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

288 enrolled 21 charts

Sarcoma

Carcinosarcoma, Carcinoma, Endometrioid

NCT03872427 2026-05-04

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

54 enrolled 12 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT04195555 2026-05-04

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

3 enrolled 9 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT06360575 2026-05-04

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

20 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT02311933 2026-05-01

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

81 enrolled 9 charts

Breast

Breast Neoplasms

NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02642042 2026-05-01

Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

60 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03348631 2026-05-01

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

62 enrolled 14 charts

Gynecologic

Ovarian Neoplasms

NCT00658814 2026-04-30

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Other hematologic neoplasm

133 enrolled 10 charts

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT01522976 2026-04-30

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia